on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies: Unanimous adoption of resolutions at the 2025 General Meeting
On June 11, 2025, DBV Technologies held its Combined General Meeting in Châtillon, chaired by Michel de Rosen. During this meeting, all resolutions proposed by the Board of Directors were adopted. Details of these resolutions are available on the company's website.
DBV Technologies is a biopharmaceutical company focused on developing treatments for food allergies. Their innovative technology, Viaskin, uses a non-invasive approach to treat these allergies, with ongoing studies including peanut allergy in children. The company is listed on Euronext Paris and the Nasdaq Stock Market.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news